抚中止泻散治疗腹泻型肠易激综合征的实验研究

Experimental Study on Diarrhea-Predominant Irritable Bowel＇Syndrome Treated with Fuzhong Zhixie Powder

为探讨抚中止泻散治疗腹泻型肠易激综合征（D-IBS）的作用机制，将75只SD大鼠随机分为正常组、模型组、马来酸曲美布汀组、抚中止泻散小剂量组和抚中止泻散大剂量组，每组15只，除正常组外均制作D-IBS模型。2周后加用相应药物治疗2周。检测各组大鼠血浆中血管活性肠肽（VIP）、血浆胃动素（MTL）含量，抽测结肠组织变化。结果显示，与模型组比较，各给药组血浆中VIP含量显著下降（P〈0．01）；马来酸曲美布汀组和抚中止泻散大剂量组血浆MTL含量显著下降（P〈0．05，P〈0．01）。结果表明，抚中止泻散能够降低D-IBS模型大鼠的血浆VIP、MTL含量，其治疗D-IBS的机制在于通过调节VIP、MTL等胃肠唰素的分泌与释放，从而调整胃肠动力及水、电解质的分泌与吸收。

The aim of this paper was to explore the mechanism of Fuzhong Zhixie powder（the name of Chinese drug fomula） in the treatment of diarrhea-predominant irritable bowel syndrome（D-IBS）. Seventy- five SD rats were randomly divided into five groups： normal group, model group, Trimebutine Maleate group, group[of Fuzhong Zhixie Powder in low dose, and group of Fuzhong Zhixie Powder in high dose, 15 rats for each. All groups were made into D-IBS models except the normal group. Two weeks later, all groups were treated with their corresponding drugs for 2 weeks. The level of vasoactive intestinal peptide （VIP）and plasma motilin （MTL）were measured and sampling tests were conducted on colon tissue chan- ges, The results showed that compared with the model group, the plasma levebof VIP was signiffcantly lower in the treatment groups（ P d0.01）; the plasma level of MTL in both Trjmebutine Maleate group and group of Fuzhong Zhixie Powder ii~ high dose were significantly decreased （ P 〈0.05, P 〈0.01）. It is concluded that Fuzhong Zhixie Powder could lower the plasma level of VIP and MTL in rats by regulating the secretion and release of gastrointestinal hormones, thus adjusting gastrointestinal motility, as well as the secretion and absorption of water and electrolytes.